View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 17, 2019updated 12 Jul 2022 11:59am

Axsome’s Phase III GEMINI trial of depression drug meets endpoints

Axsome Therapeutics has reported positive results from the Phase III GEMINI clinical trial of AXS-05 in patients with major depressive disorder (MDD).

Axsome Therapeutics has reported positive results from the Phase III GEMINI clinical trial of AXS-05 in patients with major depressive disorder (MDD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

AXS-05 is an investigational, oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist being developed to treat central nervous system (CNS) disorders, including MDD.

The drug candidate consists of dextromethorphan and bupropion. It is thought to enable improved communication between brain cells and increase serotonin, noradrenaline and dopamine levels.

GEMINI is a randomised, double-blind, multi-centre, placebo-controlled study conducted to investigate a twice-daily dose of the drug candidate for six weeks in a total of 327 patients with moderate-to-severe MDD.

The primary endpoint was the change in the mean Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week six, compared to placebo.

AXS-05 met the primary endpoint with a statistically significant decrease in the MADRS total score. At week six, the mean decrease from baseline was 16.6 points with AXS-05 versus 11.9 points with placebo.

In addition, the drug candidate led to improvements in depressive symptoms, demonstrating statistical significance on the MADRS total score at week one, the key secondary endpoint.

Statistically significant improvements were also observed on all secondary endpoints at week six, including remission, disease severity, functional impairment and quality of life.

At week six, remission from depression was experienced by 39.5% of patients treated with AXS-05 compared to 17.3% on placebo.

The drug candidate was found to be well-tolerated, with the most common adverse events being nausea, dizziness, headache, somnlence, diarrhoea and a dry mouth. Rates of adverse events-related discontinuation were low across the study groups.

Axsome Therapeutics CEO Herriot Tabuteau said: “With GEMINI and the previously completed ASCEND study, the efficacy of AXS-05 in major depressive disorder has now been demonstrated in two positive well-controlled trials, enabling the filing of an NDA for AXS-05, which is anticipated in the coming year.”

In March this year, the US Food and Drug Administration (FDA) awarded breakthrough therapy designation for AXS-05 to treat MDD.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena